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ABSTRACT Tuberculosis is the single most serious 
infectious disease worldwide. The respiratory tract is 
the primary site of infection by Mycobacterium 
tuberculosis (MTB). A number of immunogenic 
components of the cell wall of MTB, if delivered to 
the lungs as aerosols, can be used to study the local 
immune response. The site of deposition of these 
aerosols can be employed to control their residence 
time in the lungs. Muramyl dipeptide (MDP) aerosols 
were delivered to alveolar macrophages in the lungs 
of rodents. Guinea pig macrophages harvested by 
bronchoalveolar lavage were examined by 
differential interference contrast microscopy for 
morphological changes indicative of activation. 
Bronchoalveolar lavage fluid was analyzed for the 
presence of alkaline phosphatase, lactate 
dehydrogenase, N-acetyl-glucosaminidase (NAG), 
and total protein content. Rat alveolar macrophages 
were studied for the production of nitric oxide, by 
induction of nitric oxide synthase. Twenty-four hours 
following exposure to an aerosol of MDP, alveolar 
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Macrophages 
macrophages exhibited morphological characteristics 
(spreading and pseudopodia), enzyme activity (NAG 
50% above control), and production of the reactive 
intermediate nitric oxide. Rat macrophages subjected 
to aerosol exposure to MDP when challenged with a 
second dose of MDP or lipopolysaccharide exhibited 
a linear dose response as measured by nitric oxide 
production. These studies indicate that the topical 
delivery of an MTB bacterial cell wall component, 
muramyl dipeptide, results in activation of alveolar 
macrophages. This approach may be useful in 
elucidating elements of the immune response to 
MTB. 
INTRODUCTION  
One third of the world’s population is infected with 
Mycobacterium tuberculosis (MTB). Of the 8 million 
individuals manifesting the disease in the last year, 
almost 3 million have died. The lung is the primary 
site of infection by this microorganism and the major 
route of entry for dissemination to the remote tissues 
(1). Pulmonary tuberculosis is a chronic, slowly 
advancing disease against which cell-mediated 
immunity, rather than humoral immunity, is the 
major defense mechanism (2). Understanding the 
influence of MTB-derived immunogenic molecules 
on local elements of the cell-mediated response may 
elucidate key elements of the initial stages of 
infection.  
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Alveolar macrophages (AMs) are the primary cells 
involved in cell-mediated immunity of the lung. 
Macrophages become activated in the presence of 
immunomodulators. These biologically derived and 
active agents increase the intrinsic host defense to 
pathogenic microorganisms. AMs are phagocytic 
cells that secrete enzymes, cytokines, and reactive 
chemical intermediates to promote removal of 
particulate matter and invading microorganisms from 
the lung. AMs are an important element of the initial 
immune response in the lungs and an attractive 
aerosol delivery target because they comprise 95% of 
the nonadherent cells in the lung and possess cell-
surface receptors for the known immunostimulants, 
muramyl dipeptide (MDP) and lipopolysaccharide 
(LPS). 
Muramyl peptides [derived from Bacille Calmette-
Guerin (3)], components of the MTB bacterial cell 
wall, have been shown to induce an immune response 
following uptake by peritoneal macrophages (4). 
These components of the bacterial cell wall have 
been delivered to macrophages in sites other than the 
lungs by incorporation in liposomes (5-8). Deposition 
in the lower lungs depends on particle size and is 
achieved optimally by particles in the 1- to 5-μm 
particle size range (9). The challenges of delivering 
these agents to the lung include factors influencing 
residence time such as enzymatic degradation and 
mucociliary transport, both of which remove 
deposited materials from the lungs (10). Inhalation of 
aerosols provides a noninvasive delivery system that 
physically targets the lung as the desired site of 
pharmacological effect. In the present studies, the 
intention was to study the local immune response 
elicited by a specific bacterial cell wall component. 
In general, localized delivery minimizes systemic 




Adjuvant Peptide, 98% peptide, Sigma, St. Louis, 
MO) is a nonpyrogenic component of bacterial cell 
walls. It enhances both humoral and cellular 
immunity and stimulates macrophage cytotoxicity in 
vitro. MDP is not metabolized but is rapidly 
eliminated in vivo through nephritic clearance (t1/2 < 
20 minutes). LPS from Escherichia coli (Serotype 
055:B5, Sigma) is an endotoxin derived from 
bacterial cell walls. Disodium fluorescein (ICN 
Biomedical, Aurora, OH) was employed as a marker 
substance to evaluate dose delivered to the animals. 
Various cofactors, including -nicotinamide adenine 
dinucleotide phosphate, reduced form (NADPH, N-
1630, Sigma); flavin adenine dinucleotide (FAD, F-
6625, Sigma); and (6R)-5,6,7,8-tetrahydro-L-
biopterin dihydrochloride (BH4, 153622, ICN 
Biomedicals), were employed to study induction of 
nitric oxide synthase (iNOS) activity in guinea pigs. 
METHODS 
Animals were maintained at 72°F on a 12-hour 
light/12-hour dark cycle and provided food and water 
ad libitum in accordance with NIH guidelines and 
University of North Carolina Institutional Animal 
Care and User Committee protocol #95-264-0-B. 
Aerosol Generation and Delivery 
 
Figure 1: Schematic diagram of the aerosol delivery 
system and exposure chamber. 
A nebulizer (Acorn II; Marquest Medical, 
Englewood, CO) was used to deliver MDP solution 
(100 μg/mL in 0.9% w/v saline) at an air pressure of 
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50 psig into a rodent-modified whole-body ("nose-
only") exposure chamber, as shown in Figure 1 (11). 
Animals were restrained in polypropylene tubes to 
direct aerosols primarily to the nose in a glass whole-
body exposure chamber. Guinea pigs (Dunkin 
Hartley, 325-375 g; Charles River, Wilmington, MA) 
or rats (Sprague Dawley, 225-275 g; Charles River) 
were exposed to an aerosol for a period of 10 minutes 
(5 mL of solution). Aerodynamic droplet sizes were 
estimated by inertial impaction (Mark II, Eight Stage 
Non-Viable; Graseby-Andersen, Smyrna, GA) from 
the base of the exposure chamber (Figure 1). 
Dose Delivery 
It was impractical to develop methods for analyzing 
the dose of immunomodulator administered. 
However, because nebulizer performance and animal 
breathing characteristics are well documented, 
estimates of the dose delivered could be derived. In 
addition, by using an easily detectable marker for the 
nebulizer droplets, the dose deposited could be 
estimated practically.  
Estimated doses, of 10 to 20 μg of MDP per animal, 
were based on breathing frequency (90 
breaths/minute), tidal volume (1.8 mL) (12), and 
aerosol concentration. This estimated dose was in the 
range likely to activate macrophages, considering its 
dispersion on the peripheral lung surface, determined 
by referring to the published literature (13). A group 
of animals (n = 5) were subjected to a nebulizer study 
using disodium fluorescein (100 μg/mL in 0.9% w/v 
saline) solution delivered from a 5-mL reservoir over 
a 10-minute delivery period. The Acorn II nebulizer 
was operated at 50 psig. Blood and urine samples 
were taken from which the plasma concentration 
versus time and total dose delivered could be 
estimated. Assays were conducted in glycine buffer, 
pH 9, by spectrofluorimetry (Perkin Elmer LS50B, 
Norwalk, CT) at an excitation wavelength of 516 nm 
and an emission wavelength of 486 nm. The 
estimated dose delivered was 10.62 ± 0.46 μg of 
disodium fluorescein. 
Broncho-Alveolar Lavage 
Animals were killed at specified survival intervals 
after aerosol exposure. Guinea pigs were anesthetized 
with ketamine/xylazine/acepromazine (25:12.5:1.25 
mg/kg), and the trachea was isolated by a midline 
incision. Animals were tracheostomized, and a 14-
gauge stainless steel catheter was secured with a 
suture. The animals were exsanguinated, and the 
lungs were gently perfused 3 times with a single 
volume (28 mL/kg) of normal saline at room 
temperature (14). Recovery volume was typically 
85%. Broncho-alveolar lavage (BAL) fluid was 
centrifuged and the pellet of cells was recovered. A 
number of macrophage nonspecific phagocytosis 
assays were conducted following BAL fluid 
collection (15). The saline supernatant was assayed 
for protein content and enzymatic markers of 
macrophage activation. Resuspended cells were 
counted, plated on microscope cover glasses, 
incubated for 1 hour, and fixed and examined for 
altered morphology using differential interference 
contrast microscopy. A number of slides were treated 
in vitro with MDP (100 μL, 100 μg/mL) during 
incubation. Cell types recovered from the BAL fluid 
were identified microscopically as an indication of 
cell infiltration. 
Cell Culture 
BAL fluid was centrifuged at 500g for 5 minutes 
(GS-15R Centrifuge; Beckman, Palo Alto, CA), and 
cells were recovered as a pellet. Cells were 
resuspended in RPMI 1640 media supplemented with 
10% heat inactivated fetal calf serum, and 2 mmol/L 
glutamine. Total cell numbers were counted in a 
hemacytometer and were adjusted to a cell density of 
2 × 106/mL. 
Cell suspensions (100 μL) were plated onto standard 
microscope slides and incubated for 1 hour at 37°C, 
95% RH. Some slides were treated in vitro with MDP 
(100 μL, 100 μg/mL) prior to incubation. Slides were 
rinsed in normal saline to remove nonadherent cells 
and fixed with 1% paraformaldehyde. Adherent cells 
were primarily macrophages (>95%) as determined 
by a differential staining technique (Camco Stain 
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Pak; Cambridge Diagnostic Products, Ft. Lauderdale, 
FL). 
Fixed slides were mounted with cover slips and 
examined by light microscopy (Nikon FXA Research 
Light Microscope, Garden City, NJ) using 
differential interference contrast imaging. Cells were 
visually evaluated for altered morphology and were 
scored as activated if they exhibited increased 
cytoplasmic area, visible pseudopodia, or elongated 
appearance relative to controls. 
Nitric Oxide Synthesis 
Resident alveolar macrophages were harvested from 
untreated guinea pigs by BAL, resuspended in 
supplemented RPMI media, and seeded in 96-well 
culture plates (2 × 105 cells/well). Cells were 
incubated for 1 hour at 37°C, 95% RH, 10% CO2 to 
allow adherence and then gently rinsed twice with 
culture media to remove any nonadherent cells. 
Elicited macrophages were obtained by pretreating 
animals with MDP aerosols 24 hours prior to BAL 
and macrophage harvest. This process increased the 
cell counts and allowed evaluation of the influence of 
in vivo activation on NO production. Cells were 
treated in vitro with saline or serial dilutions of the 
immunostimulants MDP or LPS (0.001 ng/mL-100 
μg/mL), with a final well volume of 200 μL. Various 
cofactors were added to some wells, including 
NADPH (1 mmol/L), FAD (10 mmol/L), CaCl2 (2 
mmol/L), BH4 (10 or 100μM), and mixtures thereof. 
Cells were incubated for various time periods, 
usually 24 hours, under the above conditions. Final 
cell viability was assessed by the crystal-violet 
methanol method (16) and was typically 90%. Nitric 
oxide (NO) in NO2 production was evaluated by 
incubating 100 μL of cell media supernatant with 100 
μL Griess reagent (0.05% napthylethylenediamine, 
0.5% sulfanilamide, 2.5% phosphoric acid) for 15 
minutes at room temperature. Absorbance was 
measured in a microplate reader (Molecular Device, 
Sunnyvale, CA) at 562 nm, and samples were 
quantitated against sodium nitrite standards in 
distilled water. 
BIOCHEMICAL ASSAYS 
Alkaline Phosphatase  
Alkaline phosphatase (AP) is a lysosomal enzyme 
indicative of tissue damage. AP catalyzes the 
reduction of p-nitrophenol phosphate to p-nitrophenol 
and phosphoric acid in the presence of magnesium 
ions and adenosine monophosphate. The rate of 
change in absorbance at 400 nm is directly 
proportional to AP activity in the sample.  
Lactate Dehydrogenase 
An increase in the cytosolic enzyme lactate 
dehydrogenase (LDH) in the bronchoalveolar lavage 
fluid is indicative of cell damage and Iysis. A 
commercially prepared kit and controls (Accutrol 
Normal, Sigma) were employed in this assay. LDH 
catalyzes the oxidation of lactate to pyruvate with 
simultaneous reduction of nicotinamide adenine 
dinucleotide (NAD). Formation of reduced NAD 
(NADH) results in an increase in absorbance at 340 
nm. The rate of change in absorbance at 340 nm is 
directly proportional to LDH activity in the sample. 
N-acetyl- -D-glucosaminidase 
N-acetyl- -D-glucosaminidase (NAG) is an enzyme 
secreted by alveolar macrophages during 
phagocytosis of particulate material. A commercially 
available kit was employed to assay for this enzyme 
(Boehringer Mannheim, Indianapolis, IN). 3-
Cresolsulfonphthaleinyl-N-acetyl- -D-glucosaminide 
is hydrolyzed by NAG with the release of 3-
cresolsulfonphthalein sodium salt (3-cresol purple), 
which is measured spectrophotometrically at 580 nm. 
Total Protein 
Increases in total protein are suggestive of 
transudation of plasma protein (ie, alterations in the 
alveolar:capillary barrier). Total protein was 
determined using Pierce Coomassie Plus Protein 
Assay Reagent (Pierce, Rockford, IL). Sample 
protein concentrations were determined from a 
standard curve using bovine serum albumin standards 
(Sigma). The assay was based on the absorbance shift 
from 465 to 595 nm that occurs when Coomassie 
Blue G-250 binds to proteins in an acidic solution. 
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Reactive Nitrogen Intermediates 
NO is produced by induction of iNOS in activated 
alveolar macrophages as a chemical defense (17,18). 
NO degrades rapidly to nitrite in solution, which can 
be colorimetrically assayed (Greiss Reagent). Rats (n 
= 5) were treated with saline or MDP aerosols. AMs 
were harvested 24 hours after exposure and cultured 
in 96-well plates (n = 3/animal) in the presence or 
absence of a secondary in vitro challenge of MDP or 
LPS. LPS was selected as a positive control and NO2 
was then measured in the cell supernatant. Student’s t 
test (unpaired, 1-tailed) was conducted on mean 
values. 
RESULTS 
Aerosols with mass median aerodynamic diameters 
of 2 μm and geometric standard deviations of 2 were 
delivered to rodents. Theoretical and practical studies 
of the dose of MDP delivered were approximately 
equivalent (10-20 μg). It should be noted that this 
dose is based on delivery to the entire respiratory 
tract. Caution should be exercised in extrapolating 
from this dose to that depositing in the periphery of 
the lungs.  
The modification to the whole-body exposure 
chamber rendered it effectively a "nose-only" 
chamber because the animal was constrained and 
unable to groom; consequently, it was unable to 
ingest an oral dose of the deposited aerosol droplets. 
Guinea pig AMs exhibited altered morphology 
indicative of activation after MDP aerosol exposure. 
These effects were time and dose dependent. 
Enzymatic markers of activation were also increased 
in BAL fluids after exposure. Cellular influx to the 
lung was minimal in the period during which animals 
were studied. MDP stimulated rat AM NO 
production both in vitro and in vivo.  
Cells from saline aerosol-treated control animals 
were typically rounded in appearance, as indicated in 
Figure 2. The same cells treated in vitro for 1 hour 
with MDP exhibit morphological indicators of 
activation, such as the extension of pseudopodia and 
oblate morphology. 
 
Figure 2: Photomicrographs of guinea pig alveolar 
macrophages (a) 24 hours following exposure to a 
saline aerosol and; (b) the same cells (different field) 
treated for 1 hour with MDP in vitro. 
Figure 3 depicts cells from animals treated with MDP 
in aerosol form; numerous activated cells with 
pseudopodia and oblate morphology are evident 24 
hours after exposure. Additional in vitro treatment 
with MDP increased the percentage of activated cells, 
and many showed an increase in cytoplasmic area. 
 
Figure 3: Photomicrographs of guinea pig alveolar 
macrophages (a) 24 hours following exposure to an 
aqueous MDP aerosol and; (b) the same cell population 
(different field) treated for 1 hour with MDP in vitro. 
Animals treated with MDP in aerosol form showed 
fewer activated cells 48 hours after exposure than at 
24 hours after exposure, as illustrated in Figure 4. 
However, cells remain primed to respond because in 
vitro treatment with MDP increased the percentage of 
activated cells with respect to the control values. 
 
Figure 4: Photomicrographs of guinea pig alveolar 
macrophages at (a) 48 hours following exposure to an 
aqueous MDP aerosol and; (b) the same cell population 
(different field) treated for 1 hour with MDP in vitro. 
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Figure 5: Photomicrographs of guinea pig alveolar 
macrophages (a) exposed twice at intervals of 24 hours 
to an aqueous MDP aerosol and (b) the same cell 
population (different field) treated for 1 hour with MDP 
in vitro. 
Cells from animals treated with MDP aerosols on 2 
consecutive days show a large number of activated 
cells at 48 hours. Subsequent in vitro treatment with 
MDP has little additional effect. Figure 5 illustrates 
these phenomena. 
Table 1 illustrates the enzyme activity and cell 
infiltrate following various muramyl dipeptide 
treatments. Neutrophil, basophil, and eosinophil 
numbers did not change following exposure. The 
number of lymphocytes tripled up to 72 hours, 
whereas monocyte and macrophage numbers peaked 
at 5- to 8-fold higher than untreated control at 24 to 
48 hours, returning to baseline at 72 hours. 




Total Cell Number 
(x106) 
N-Acetyl Glucosaminid-ase (% 
above Control) 
Alkaline Phosphatase (% 
above control) 
Total Protein (% 
above control) 
0a 1.90 - - - 
6 6.11 -15.4 14.9 -14.6 
19 9.18 29.3 23.4 74.0 
24 8.57 58.0 44.7 74.0 
48 7.07 37.9 48.9 78.0 
48b 15.40 196 74.5 115.6 
a. Saline treated control animals  
b. Two in vivo exposures on successive days. 
TABLE ΙΙ: Qualitative summary of the morphological 
changes (by number) of the guinea pig alveolar 
macrophage populations observed: - < 10% spreading; 
± 10-20% spreading, some tvisible pseudopodia; + 20-
35% spreading, numerous cells with pseudopodia or 









followed by in vitro 
exposure to MDP 
0a - ± 
6 ± ± 
19 + ++ 
24 + ++ 
48 ± + 
48b ++ ++ 
a. Saline treated control animals. 
b. Two in vivo exposures on successive days 
Lactate dehydrogenase activity did not change in 
respect to control values in any of the studies. The 
remaining enzyme levels and total protein increased 
at 24 to 48 hours in respect to controls, as shown in 
Table 1. The increase in NAG, by 58% at 24 hours, is 
indicative of the phagocytic activity of the 
macrophages. The increase in alkaline phosphatase, 
by 44.7% at 24 hours, represents a nonspecific local 
inflammatory response. The increase in total protein, 
by 78% at 48 hours, is indicative of the presence of 
additional enzymes and mediators resulting from the 
action of the aerosol. MDP does not contribute to the 
total protein because it is cleared rapidly. In addition, 
it can be seen that there was little change in total 
protein at early time points. Table 2 is a qualitative 
summary of the morphological changes of the 
alveolar macrophage populations observed after 
aerosol and in vitro treatments. 
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Neither resident nor elicited guinea pig AMs showed 
detectable production of nitrite under any test 
conditions. Various in vitro stimulation periods of 6, 
12, and 24 hours were examined initially, and all 
further experiments were standardized to a 24-hour 
incubation. Both resident and elicited GP 
macrophages failed to respond to LPS or MDP 
stimulation in vitro over a wide concentration range. 
Elicited guinea pig AMs also failed to respond to 
LPS stimulation in the presence of various cofactors, 
including NADPH, calcium, FAD, and 2 different 
concentrations of BH4 (1 mmol/L or 100 mmol/L), 
either alone or in combination. In contrast, resident 
rat AMs showed significant nitrite production when 
stimulated with LPS (0.1, 5, and 10 μg/mL) or MDP 
(10.0 or 20.0 μg/mL). Therefore, preliminary studies 
showed that guinea pig AMs did not produce 
detectable quantities of NO, a reactive intermediate 
implicated in the immune response. In order to study 
the production of NO in response to the presence of 
MDP, a species was selected in which alveolar 
macrophages are known to exhibit iNOS activity. 
Figure 6 shows indirectly the production of NO 
detected in the form of nitrite (NO2) by alveolar 
macrophages lavaged from the lungs of rats 
following aerosol exposure to MDP, and including a 
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Figure 6: Nitrite concentration (NO2) reflecting NO 
production by rat alveolar macrophages in broncho-
alveolar lavage fluid under a variety of conditions as 
determined using Greiss reagent (Mean ± SE, n=15). 
Treatment with MDP in vitro produced a linear dose 
response in the range of 0.001 to 1 μg/mL of 1-5 
nmol NO2/10
5 cells. Treatment with LPS in vitro in 
the same concentration range resulted in 
approximately the same increase in NO production 
but over a slightly higher range, 6-12 nmol NO2/10
5 
cells. Pretreatment with MDP aerosol reduced the 
production of NO with the subsequent MDP 
treatment in vitro (0.5-2 nmol NO2/10
5 cells). MDP 
aerosol pretreatment had a significant effect on the 
NO production by cells treated with LPS in vitro (5-
22 nmol NO2/10
5 cells over the concentration range 
0.001-1 μg/mL LPS). It is clear that aerosol 
pretreatment primes the macrophage for a subsequent 
challenge. However multiple exposure to the same 
immunomodulator may condition the response. 
MDP aerosol followed by MDP in vitro resulted in a 
significant (P < .05) decrease in the mean NO 
production in comparison with the MDP treatment 
alone in vitro at all concentrations (P < .001 for 
0.001, 0.01, and 0.1 μg/mL and P < .025 for 1 
μg/mL). MDP aerosol followed by LPS in vitro 
resulted in a significant increase in the mean NO 
production compared to the LPS treatment alone in 
vitro at 1 μg/mL (P < .001) and a significant decrease 
at 0.001 μg/mL (P < .05) but had no effect at 0.01 
and 0.1 μg/mL (P > .05).  
DISCUSSION 
Morphological changes were observed in alveolar 
macrophages following treatment of guinea pigs with 
aerosols of MDP. These changes were concomitant 
with increased enzyme activity. The production of N-
acetyl-glucosaminidase is an indicator of phagocytic 
activity and is consistent with the observation that 
some of the cells observed microscopically produce 
pseudopodia following MDP treatment. There was 
also some indication of a nonspecific immune 
response, as indicated by elevated alkaline 
phosphatase activity and total protein concentrations 
in BAL fluid. 
These studies indicated that aerosol delivery of 
peptide immunomodulators directly to rodent lungs 
resulted in activation of the local cellular immune 
system. They also demonstrated a “priming” effect of 
MDP on AMs, as indicated by the enhanced response 
of cells stimulated in vivo to secondary in vitro 
challenges. 
The advantage of an aerosol delivery approach is that 
the immunogen is presented in a manner similar to 
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the microorganism. Consequently, the local effects 
are of direct relevance to the disease state. In 
addition, the presence of airway epithelial cells and 
proximity to the interstitium and vasculature allow 
the influence on the local environment to be studied. 
Control rat AMs showed low basal levels of iNOS 
activity but responded to in vitro MDP or LPS 
exposure, as depicted in Figure 6. Cells from animals 
treated with MDP in aerosol form also showed low 
basal levels of iNOS activity, but became refractory 
to a second MDP challenge in vitro. However, their 
response to an LPS challenge in vitro was enhanced 
relative to controls treated with saline. 
A variety of markers of inflammation or immunity 
can be employed to evaluate aerosol challenges to the 
lungs. Cell and enzyme studies have been described. 
There are no commercially available reagents for 
guinea pig cytokines/chemokines. However, this 
species, in common with humans, does not readily 
exhibit iNOS activity. It remains to be seen whether 
either species requires specific cofactors to exhibit 
such a response. This is a subject of great interest to 
molecular immunologists at present. The rat alveolar 
macrophages exhibit iNOS activity and were 
consequently selected for evaluation of the 
biochemical responses to MDP aerosol delivery. The 
apparent contradiction of the response of rats, based 
on nitrite production, and guinea pigs, based on cell 
morphology, to MDP aerosol followed by MDP in 
vitro alone may represent a fundamental difference in 
these species’ immunological response to such a 
challenge. Rats apparently become refractive to a 
second challenge with the same immunomodulator, 
whereas guinea pigs exhibit an enhanced response 
under the same experimental conditions. This 
difference has implications for the selection of an 
animal model, in regard to relevance to humans. 
Models for human lung diseases in rodents are 
numerous, and these studies form the basis for a more 
detailed investigation of the local immunological 
response. Future work will focus on more specific 
aspects of the inflammatory response, including 
further identification of infiltrating cell types, 
evaluation of cytokine/chemokine production, and 
cytotoxicity of activated macrophages against 
bacterial targets. These studies are of particular 
significance because methods of studying the 
relationship between acquired immunodeficiency 
syndrome and serious opportunistic bacterial 
infections are required. 
CONCLUSION 
Models for human lung disease in guinea pigs are 
numerous. Little is known of the immunological 
activity of the lung at the molecular level in this 
species. These studies initiate a program to evaluate 
the guinea pig immune response. Treatment of 
macrophages with MDP in vitro is known to induce 
activation. Our preliminary data are indicative of 
alveolar macrophage activation after aerosol 
administration in vivo. 
Exposed animals exhibit a cellular influx to the site 
of administration, and the alveolar macrophages 
exhibit altered morphology relative to controls. Total 
protein and cytosolic enzyme levels of NAG and 
alkaline phosphatase are also elevated, indicating a 
nonspecific immune response. These effects are time-
dependent relative to residence time in the lung. Dose 
dependence is also demonstrated between doubly- 
and singly-exposed animals. 
The basis of conducting aerosol-exposure 
experiments and evaluating the biological outcome of 
administering immunomodulators directly to the 
lungs has been established. Further work is required 
to investigate the detailed biochemical and 
immunological responses of alveolar macrophage 
from different species to activation using 
immunomodulators.  
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